.
Acute coronary syndrome (ACS) remains as a major cause of mortality globally.1 Lipid management is an important part of secondary prevention for the ACS. ACC 2022 expert consensus decision pathway (ECDP) on non-statin therapy indicated that low-density lipoprotein cholesterol (LDL-C) goal for very high-risk patients should be <55mg/dL.2 Northern Arizona Healthcare (NAH) initiated evolocumab in their hospital formulary in March, 2021 to comply with the guideline directed lipid management in ACS patients. There is a dearth of real-world evidence whether the ECDP directed LDL-C contributes to the reduction of hospital readmissions. This study aims to investigate if the ECDP recommended LDL-C <50mg/dL is associated with the reduction of hospital readmissions in patients with ACS. A retro-prospective single center study with a data collection from May, 2022 to June, 2024 was conducted. The IRB was approved by NAH in January, 2024 for ELAINE (Early Lipid management in ACS patients Improves cardiovascular outcomes with Non-statin therapy, Evolocumab). SPSS (Version 29) was used for propensity score, missing value analysis, t-tests, repeated measures ANOVA, linear and logistic regressions and Kaplan Meier survival analyses. G*Power was used for the power analysis3. A total of 157 subjects with 2:1 ratio of control and intervention groups were examined. Three missing values of baseline and 3 follow up LDL-C levels were identified as a missing completely at random (Little’s MCAR χ2 = 9.045, df = 10, p-value = .528) and replaced with the mean value for the baseline LDL-C. For the matching control group, propensity score predicting likelihood of involving in intervention group as a function of age, sex, BMI, CAD, STEMI, and PAD was calculated. Mean age of the subjects was 59.6 and 71% were male and White. A total of 85% of the subjects (n=133) were on statin as a background therapy followed by 20.3% for icosapentethyl, 15.2% for ezetimibe, and 8.3% for statin intolerance. A total of 34% (n=53) of the subjects were on evolocumab and 66% (n=104) were control group. LDL-C reduction in intervention was 65% compared to 7% in control group at second follow up (t=-2.51, df=50, p=.015) but the LDL-C reduction over time by evolocumab group was not significant in repeated measures ANOVA (F=1.725, df=1, p=.202) and no differences were found in MI associated or all causes of event associated hospital readmissions in Kaplan Meier (χ2=2.84, df=1, p=.092). The novel therapy of PCSK9 inhibitor in patients with ACS was effective in significant LDL-C reduction. However, the ECDP directed LDL-C<50mg/dL did not contribute to the reduction of MI associated or all causes of hospital readmissions in an acute care setting. The result is not considered conclusive in the setting of a single center and an ongoing prospective study. A small sample size could create random variations resulting in type II error.
Acute coronary syndrome (ACS) remains as a major cause of mortality in the U.S. The current landscape of low-density lipid cholesterol (LDL-C) management has been a major contributing factor of reducing atherogenic associated events. Studies demonstrated that PCSK9 inhibitors, such as evolocumab, reduce LDL-C by 60%.1-2 There is dearth of real-world evidence of the effective duration of non-statin therapy, evolocumab, in a hospital setting. This study aims to investigate the effective duration of non-statin therapy, evolocumab, in addition to the background statin therapy in patients with ACS. A retro-prospective single center study with a data collection from May, 2022 to June, 2024 was conducted. The IRB was approved by Northern Arizona Healthcare in January, 2024 for a project ELAINE (Early Lipid management in ACS patients Improves cardiovascular outcomes with Non-statin therapy, Evolocumab). SPSS (Version 29) was used for propensity score, missing value analysis, t-tests, repeated measures ANOVA, linear and logistic regressions and Kaplan Meier survival analyses. For the power analysis, G*Power was used.3 A total of 157 subjects with 2:1 ratio of control and intervention groups were examined. Three missing values of baseline and 3 follow up LDL-C levels were identified as a missing completely at random (MCAR) (Little’s MACR χ2 = 9.045, df = 10, p-value = .528). For the matching control group, propensity score predicting likelihood of involving in intervention group as a function of age, sex, BMI, CAD, STEMI, and PAD was calculated and matched accordingly. Mean age of the subjects was 59.6 years and 71% were male and White. A total of 85% of the subjects (n=133) were on statin followed by 20.3% for icosapentethyl (n=32), 15.2% (n=24) for ezetimibe, and 8.3% (n=13) for statin intolerance. A total of 34% (n=53) of the subjects were on evolocumab and 66% (n=104) were control group. The LDL-C reduction was 65% compared to 7% reduction in control group at second follow up (t=-2.51, df=50, p=.015). The use of evolocumab at a mean duration of 300 days significantly contributed to the reduction of hospital readmissions secondary to MI (b=.89, t=3.7, p=.021) but no longer predicted the MI associated hospital readmissions after controlling for age, sex, BMI and other covariates (b=1.27, t=10.7, p=.059) and no difference was found by sex at Kaplan Meier (χ2=2.021, df=1, p=.155). The novel therapy of PCSK9 inhibitor was effective in significant LDL-C reduction. The long duration of PCSK9 inhibitor, evolocumab use with a mean of 300 days did not contribute to the reduction of MI associated hospital readmissions controlling for age, sex, BMI and other covariates. The result is not considered conclusive in the setting of a single center and an ongoing prospective study. A small sample size also could create random variations resulting in type II error.
Developing and running an application in a local machine and serving the application as a service in a server have a unique challenge. At this point, we can run our application, and colleagues can access our dashboard remotely. But we should harden our design. Wouldn’t it be nice if the software started automatically in the event of a server reboot? Without us having to log in and start the virtual environment each time?
This practical resource is for those looking to leverage Python's power for data visualization and analysis in a user-friendly dashboard format.
Although infections caused by Clostridioides difficile have historically been attributed to hospital acquisition, growing evidence supports the role of community acquisition in C. difficile infection (CDI). Symptoms of CDI can range from mild, self-resolving diarrhoea to toxic megacolon, pseudomembranous colitis, and death. In this study, we sampled C. difficile from clinical, environmental, and canine reservoirs in Flagstaff, Arizona, USA, to understand the distribution and transmission of the pathogen in a One Health framework; Flagstaff is a medium-sized, geographically isolated city with a single hospital system, making it an ideal site to characterize genomic overlap between sequenced C. difficile isolates across reservoirs. An analysis of 562 genomes from Flagstaff isolates identified 65 sequence types (STs), with eight STs being found across all three reservoirs and another nine found across two reservoirs. A screen of toxin genes in the pathogenicity locus identified nine STs where all isolates lost the toxin genes needed for CDI manifestation (tcdB, tcdA), demonstrating the widespread distribution of non-toxigenic C. difficile (NTCD) isolates in all three reservoirs; 15 NTCD genomes were sequenced from symptomatic, clinical samples, including two from mixed infections that contained both tcdB+ and tcdB- isolates. A comparative single nucleotide polymorphism (SNP) analysis of clinically derived isolates identified 78 genomes falling within clusters separated by ≤2 SNPs, indicating that ~19 % of clinical isolates are associated with potential healthcare-associated transmission clusters; only symptomatic cases were sampled in this study, and we did not sample asymptomatic transmission. Using this same SNP threshold, we identified genomic overlap between canine and soil isolates, as well as putative transmission between environmental and human reservoirs. The core genome of isolates sequenced in this study plus a representative set of public C. difficile genomes (n=136), was 2690 coding region sequences, which constitutes ~70 % of an individual C. difficile genome; this number is significantly higher than has been published in some other studies, suggesting that genome data quality is important in understanding the minimal number of genes needed by C. difficile. This study demonstrates the close genomic overlap among isolates sampled across reservoirs, which was facilitated by maximizing the genomic search space used for comprehensive identification of potential transmission events. Understanding the distribution of toxigenic and non-toxigenic C. difficile across reservoirs has implications for surveillance sampling strategies, characterizing routes of infections, and implementing mitigation measures to limit human infection.